USA
Analytical Standards
Controlled Research Environment
Research Product
Retatrutide
1. Product Overview
Retatrutide is a synthetic research peptide that has attracted significant scientific interest for its interaction with multiple metabolic regulatory pathways. Ongoing research has explored its activity across glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems, making it a subject of investigation in metabolic, endocrine, and energy balance research. The peptide is supplied as a lyophilized research formulation and undergoes analytical testing to verify identity, purity, and consistency.
Manufactured in a controlled research environment, this product is intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | Retatrutide | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Retatrutide | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 5 mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
Retatrutide is a synthetic research peptide that has attracted significant scientific interest due to its interaction with multiple metabolic regulatory pathways. Research has explored its activity across glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems, making it a subject of investigation in metabolic, endocrine, and energy balance research.
Preclinical and clinical studies have evaluated Retatrutide in models involving metabolic regulation, glucose homeostasis, energy expenditure, and body composition research. Ongoing investigations continue to explore its unique multi-receptor activity and its role in complex metabolic signaling networks.
4. Scientific References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for the treatment of obesity. Cell Metabolism. 2022;34(9):1234-1248.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526.
- Urva S, Levine JA, Schneck K, et al. Pharmacokinetics and pharmacodynamics of the novel triple receptor agonist Retatrutide. Clinical Pharmacology in Drug Development. 2024;13(1):45-56.
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1): Mechanisms of action and therapeutic potential. Cell Metabolism. 2019;30(2):402-424.
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism. 2013;17(6):819-837.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
